Therapeutic area
Oncology biotech companies
The 15 oncology companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals | Dupixent · multiple type 2 inflammatory diseasesApproved | $17.82B2026-06-30 | — | archived |
| MRNAModerna | mRNA-1345 (RSV) · Respiratory syncytial virus (RSV) in older adultsApproved | $6.91B2026-06-30 | — | archived |
| GILDGilead Sciences | Biktarvy · HIVApproved | $3.18B2026-06-30 | — | archived |
| CRSPCRISPR Therapeutics | Casgevy (exagamglogene autotemcel) · Sickle cell disease and transfusion-dependent beta-thalassemiaApproved | $2.36B2026-06-30 | ~74 mo | maintained |
| CELCCelcuity | REVTORPYK (gedatolisib) · HR+/HER2-, PIK3CA wild-type advanced breast cancer after endocrine therapyApproved | $754M2026-06-30 | ~41 mo | maintained |
| NTLAIntellia Therapeutics | NTLA-2001 (nexiguran ziclumeran) · Transthyretin amyloidosis (ATTR) — hereditary and wild-typePhase 3 | $628M2026-06-30 | ~19 mo | maintained |
| ABBVAbbVie | Skyrizi · psoriasis, inflammatory bowel disease, and related immunology usesApproved | no filing parsed | — | archived |
| AMGNAmgen | TEPEZZA · thyroid eye diseaseApproved | no filing parsed | — | archived |
| BNTXBioNTech | ONC-392 · Non-small cell lung cancer (NSCLC)Phase 3 | no filing parsed | — | archived |
| ERASErasca | Naporafenib · NRAS-mutant melanomaPhase 3 | no filing parsed | — | archived |
| HALOHalozyme Therapeutics | Darzalex Faspro economics exposure · multiple myelomaApproved | no filing parsed | — | archived |
| INCYIncyte | Jakafi · myelofibrosis and graft-versus-host diseaseApproved | no filing parsed | — | archived |
| RXRXRecursion Pharmaceuticals | REC-994 · cerebral cavernous malformationPhase 2 | no filing parsed | — | archived |
| TERNTerns Pharmaceuticals | TERN-501 · Thyroid Eye Disease (TED)Phase 2 | no filing parsed | — | archived |
| TNGXTango Therapeutics | TNG462 · MTAP-deleted solid tumorsPhase 1 | no filing parsed | — | archived |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2027-09-28 · INCY · AXemplify-357: Axatilimab in Chronic graft-versus-host disease, first line — primary completion ClinicalTrials.gov
- 2028-01 · RXRX · ELUCIDATE: GTAEXS617 in Advanced solid tumours — primary completion ClinicalTrials.gov
- 2028-02-07 · REGN · OLYMPIA-1: Odronextamab in Previously untreated follicular lymphoma — primary completion ClinicalTrials.gov
- 2028-03 · ABBV · Venetoclax ramp-up CLL: Venetoclax in Previously untreated chronic lymphocytic leukaemia — primary completion ClinicalTrials.gov
- 2028-03 · HALO · XYOSTED adolescent: Testosterone enanthate (XYOSTED) in Male adolescent hypogonadism — primary completion ClinicalTrials.gov
- 2028-04 · ERAS · SEACRAFT-2: Naporafenib + trametinib in NRAS-mutant cutaneous melanoma — primary completion ClinicalTrials.gov
- 2028-06 · RXRX · EXS73565: EXS73565 in Relapsed/refractory B-cell malignancies — primary completion ClinicalTrials.gov
- 2028-06-19 · REGN · Dupilumab paediatric EoE: Dupilumab in Eosinophilic oesophagitis in children — primary completion ClinicalTrials.gov
- 2028-11-15 · INCY · INCB123667 ovarian: INCB123667 in Platinum-resistant ovarian cancer, cyclin E1 overexpression — primary completion ClinicalTrials.gov
- 2029-01-04 · AMGN · DeLLphi-312: Tarlatamab in Untreated extensive-stage small-cell lung cancer — primary completion ClinicalTrials.gov
- 2029-01-31 · AMGN · Etelcalcetide paediatric: Etelcalcetide in Secondary hyperparathyroidism on haemodialysis — primary completion ClinicalTrials.gov
- 2029-03 · RXRX · EXS74539: EXS74539 in Select solid tumours — primary completion ClinicalTrials.gov
- 2029-06-15 · INCY · EXCALIBUR-ET2: INCA033989 in CALR-mutant essential thrombocythemia — primary completion ClinicalTrials.gov
- 2030-01-18 · REGN · Pozelimab + cemdisiran PNH: Pozelimab and cemdisiran in Paroxysmal nocturnal haemoglobinuria — primary completion ClinicalTrials.gov
- 2031-05 · GILD · KITE-753 vs axi-cel: KITE-753 in Relapsed/refractory large B-cell lymphoma — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.